Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ: KYTX )

10.69 +0.78 (+7.87%)
Streaming Delayed Price Updated: 1:42 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kyverna Therapeutics, Inc. - Common Stock

Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Why Kyverna Therapeutics Stock Is Sinking
Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. Here's a look at the details: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
The market's excited for these stocks, but there's no rush to buy them. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.